Live: Will Webull Crush Q2 Earnings Tonight After Rising 7.5% Today?

Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

736 Articles

Chris Lange | Jan 26, 2017 at 10:35 AM EST

Short Sellers Back Off Major Biotechs

As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears…

Paul Ausick | Jan 24, 2017 at 4:01 PM EST

Gilead Sciences, DryShips Stuck in Tuesday’s 52-Week Low Club

DryShips, Gilead Sciences, BT Group, and Cascadian Therapeutics made new 52-week lows on Tuesday.

Paul Ausick | Jan 23, 2017 at 4:04 PM EST

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

DryShips, Teva, Endo Pharma, and Gilead Sciences posted new 52-week lows Monday.

Lee Jackson | Jan 23, 2017 at 9:55 AM EST

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks…

Chris Lange | Jan 12, 2017 at 9:35 AM EST

Biotech Short Sellers Run for Cover

As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what…

Lee Jackson | Jan 10, 2017 at 8:35 AM EST

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Needless to say, the past two years have been rough on biotech. The question for investors is which of the…

Chris Lange | Dec 28, 2016 at 10:10 AM EST

Biotech Short Interest Sinks

The December 15 short interest data have been compared with the previous report, and short interest was down in most…

Chris Lange | Dec 12, 2016 at 9:10 AM EST

Biotech Short Interest Remains Mixed

The November 30 short interest data have been compared with the previous report, and short interest was mixed in the…

Paul Ausick | Dec 8, 2016 at 4:04 PM EST

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

December 8, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in…

Chris Lange | Nov 28, 2016 at 7:35 AM EST

Short Sellers Grow More Aggressive on Major Biotechs

The November 15 short interest data have been compared with the previous report, and short interest increased in most of…

Jon C. Ogg | Nov 10, 2016 at 1:26 PM EST

Gilead Scores Another Hepatitis FDA Approval

Gilead Sciences has announced that the FDA has approved its once-a-day treatment for adults with chronic hepatitis B virus infection.

Chris Lange | Nov 10, 2016 at 7:20 AM EST

Short Sellers Grow More Selective on Major Biotechs

Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can…

Jon C. Ogg | Nov 6, 2016 at 10:20 AM EST

How Analysts View Value and Opportunity in Gilead After Earnings

If you just looked at formal Buy and Sell ratings from Wall Street analysts, you might assume that everything is…

Chris Lange | Nov 1, 2016 at 4:58 PM EDT

Has Gilead Finally Bottomed?

Gilead Sciences Inc. (NASDAQ: GILD) released third-quarter earnings report after markets closed on Tuesday. Despite negative news coming out on…

Chris Lange | Nov 1, 2016 at 11:15 AM EDT

What to Expect From Gilead Earnings

Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is…

1 … 22 23 24 25 26 … 50

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Back Off Major Biotechs

Gilead Sciences, DryShips Stuck in Tuesday’s 52-Week Low Club

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

Biotech Short Sellers Run for Cover

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Biotech Short Interest Sinks

Biotech Short Interest Remains Mixed

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

Short Sellers Grow More Aggressive on Major Biotechs

Gilead Scores Another Hepatitis FDA Approval

Short Sellers Grow More Selective on Major Biotechs

How Analysts View Value and Opportunity in Gilead After Earnings

Has Gilead Finally Bottomed?

What to Expect From Gilead Earnings

Live: Will Webull Crush Q2 Earnings Tonight After Rising 7.5% Today?

Cramer Warns Fintech Bulls: These Three Stocks Are Priced for Perfection

Which Big Bank Stock Has Dominated in 2026: Bank of America, Wells Fargo, or Bank of New York Mellon Corp.?

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

At 88, He Still Climbs Ladders at His Shoe Store. His Age Ended the Earnings Test, but Not the Social Security Tax.

Housing Starts Plunge 10% as Mortgage Rates Climb to 6.75%, Builders Brace for Demand Collapse

Cramer Warns Fintech Bulls: These Three Stocks Are Priced for Perfection

Which Big Bank Stock Has Dominated in 2026: Bank of America, Wells Fargo, or Bank of New York Mellon Corp.?

Gilead Sciences : GILD

All Gilead Sciences Articles

Short Sellers Back Off Major Biotechs

Gilead Sciences, DryShips Stuck in Tuesday’s 52-Week Low Club

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

Biotech Short Sellers Run for Cover

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Biotech Short Interest Sinks

Biotech Short Interest Remains Mixed

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

Short Sellers Grow More Aggressive on Major Biotechs

Gilead Scores Another Hepatitis FDA Approval

Short Sellers Grow More Selective on Major Biotechs

How Analysts View Value and Opportunity in Gilead After Earnings

Has Gilead Finally Bottomed?

What to Expect From Gilead Earnings

Live: Will Webull Crush Q2 Earnings Tonight After Rising 7.5% Today?

Cramer Warns Fintech Bulls: These Three Stocks Are Priced for Perfection

Which Big Bank Stock Has Dominated in 2026: Bank of America, Wells Fargo, or Bank of New York Mellon Corp.?

Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?

Featured Reads

At 88, He Still Climbs Ladders at His Shoe Store. His Age Ended the Earnings Test, but Not the Social Security Tax.

Housing Starts Plunge 10% as Mortgage Rates Climb to 6.75%, Builders Brace for Demand Collapse